Securing half of the overseas vaccine people… Are there any disruptions to the vaccination schedule (CG)▶ Click here for a larger view
–
As the corona19 vaccine is expected to be vaccinated in Korea from the beginning of next month as early as next month, attention is focused on what will be the’Korea No. 1’vaccine.
According to the medical community and quarantine authorities on the 22nd, Korea has signed a contract to supply the Corona 19 vaccine with four overseas pharmaceutical companies such as AstraZeneca, Janssen, Pfizer, and Modena.
Among these, the vaccine that the government initially predicted to be the fastest to be introduced is AstraZeneca.
This is because AstraZeneca is the only vaccine that is being reviewed by applying for an item permission from the Ministry of Food and Drug Safety. AstraZeneca vaccine will be approved in February. Pfizer’s vaccine is in the’preliminary review’ stage before full-scale product approval screening.
However, when looking at the status of overseas vaccinations alone, Pfizer vaccines are leading the way.
Pfizer vaccine is being vaccinated in the United States, Israel, the United Kingdom, Saudi Arabia and Canada.
Countries that have started vaccination against AstraZeneca are India and the United Kingdom, and the number is quite small.
In fact, Pfizer’s products will be promisingly reviewed for vaccines that will be delivered to Korea in early February through the international project’Covax Facility’. Pfizer Pharmaceutical Korea also announced that it would apply for an item permission to the Ministry of Food and Drug Safety within this month.
However, it is unclear whether the Pfizer vaccine, which has not yet applied for permission, can be vaccinated in early February through the usual procedure.
As a result, there is a possibility that the Pfizer vaccine will be introduced in Korea through the’special import’ procedure in addition to product approval.
The special import of medicines is a system that allows the import of drugs that are not licensed in Korea from abroad in order to cope with the public health crisis such as an infectious disease pandemic.
In June of last year, the Ministry of Food and Drug Safety approved a special import for the treatment of Corona 19 from Gilead Sciences’Remdesivir’.
At that time, the Ministry of Food and Drug Safety appreciated the effect of remdesivir on reducing the treatment period for severely ill patients with Corona 19. It was also considered that remdesivir was used overseas as well for the treatment of Corona 19.
Kim Sang-bong, head of the Bio-Pharmaceutical Bureau of the Ministry of Food and Drug Safety, told Yonhap News Agency, “Currently, the KCDC has not confirmed the type of vaccine as Pfizer from Kovacs Facility.” Said.
[연합뉴스]
Copyrights ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited
–
